Therefore, to maximize the enhancement of macrophage phagocytosis, CD47/SIRPα blockade antibodies can be combined with tumor-opsonizing therapeutic antibodies that mount pro-phagocytic signaling through Fc/Fcγ interactions. This evidence concerns the gene SIRPA and neoplasm.